Premium increases: The Medicare benefit open enrollment period from November 15, health advocates warn that the beneficiaries with premium increases and forms are not able medication that you might need, they are confronted, after reports the San Francisco Chronicle. Chronicle that about 75 percent nationwide nationwide see if if they keep their current drug plan. Following Tricia Neuman, a Kaiser Family Foundation vice president and director of the Foundation Medicare Policy Project ‘It may the same old thing the same old thing and not its value changes http://edmdrx.com . But in fact, be change the plans and consumers can is better ,, J. Addition, could million beneficiaries of low income disabilities who disabilities who are dually for Medicare and Medicaid new drug new drug plans in 2008 that ‘may or may not on their drugs, ‘the Chronicle reports (Colliver, San Francisco Chronicle, Reprinted with permission from you to the entire Kaiser Daily Health Policy view Report search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report is for Kaiser network. A free service of the Henry J. Released Kaiser Family foundatio 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Daily Health Policy Report highlights recent developments in Medicare Rx BenefitSeveral newspapers recently about the developments related to the Medicare prescription drug benefit reported. Summaries appear below. Benefit the humble income – : speaker on Monday at a Capitol Hill Forum, organized by the Alliance for Health Reform sponsored discussed problems with enrollment and access to medicines for low-income Medicare beneficiaries Drug Plan and persons with disabilities, CQ HealthBeat reports. According to Stuart Guterman, director of the Commonwealth Fund ‘s Program on Medicare ‘s future, 48 percent of people with incomes up to 150 percent of the federal poverty level are not aware that they are entitled to the low income groups , and a disproportionate number of them are black or Hispanic or at the lowest end of the wage scale. Laura Summer, a researcher at the Georgetown University Health Policy Institute, said two million low-income beneficiaries automatically to a new plan in 2008, could not medication medications, they eat are switched, adding that the beneficiaries might have to forgo needed medicines under while. Working through the appeal process policy director policy director John Rother for changes in the way Medicare premium benchmarks calculated so that low-income beneficiaries are in the same plans from year to year yet called. He also urged lawmakers asset test changes in Medicare legislation, as are later this year .
Forward-Looking StatementThis release contains forward-looking statements in relation to the future therapeutic and commercial potential of Isis ‘, Alnylam is and Regulus ‘ business plans are, technology and intellectual property, Micro RNA therapeutic has found and develops in conjunction of Regulus. Every statement describe Isis ‘, of Alnylam or Regulus ‘ aims, expectations, financial and other projections, intent and belief is an forward-looking statement and should serve as one AT Risk or loss, including those statements that are described as such party objectives are. Such statements involve to risks and uncertainties, particularly those resulting from the process of discovery, development and marketing of safely and effectively safe and effective for use as an human therapeutic, and with a desire about to build a transaction with these products. June 2008 which forward-looking looking statements well party by assumption when they will never come into and according to the findings could be materially different than expressed or silently forward-looking statements at such. Even though these forward-looking statements to reflect the management’s best knowledge by each that party, these statements are will based only on facts and factors current announced by Isis, Alnylam is or Regulus, as the the case can base. As the result, It not depend on not to rely on these forward-looking statements. Of these and other risks relating to Isis ‘, Alnylam is and Regulus ‘ programs will be extra details additional detail in its annual report Isis onto the form 10-K for the fiscal year ending In December 2007 describes, and Quarterly Report on Form 10-Q for the quarter ended 30 June 2008, and Alnylam is for on Form 10-K for the period ended December 2007 Quarterly Report on Form 10-Q to the quarter ended 30 June 2008, which is on file with the SEC. Screens of this and other documents are available from Alnylam or Isis.
‘Use of See larger Versus Minor Drug Safety data bases Before Regulatory Approval: The Trade-Offs ‘Health Affairs: In the Web the exclusive, Shelby Reed, one associated professor of medicine at Duke University clinical Research Institute and his colleagues are the potential cost and benefits that. At to have larger samples at preapproval clinical trial for new drugs The researchers used developed a model order the expected incremental number adverse drug reactions the avoid once a medicament gains FDA approval might appreciate. The study shows to which more preapproval clinical trials was able to an economical way to reduce adverse drug reactions. A web exclusive perspective to the trial be available online also responsive .